Core Viewpoint - Nanjing Hailin Pharmaceutical Co., Ltd. is preparing for the election of its fifth board of directors, following the completion of the fourth board's term, in accordance with relevant laws and regulations [1][2]. Group 1: Board Composition - The fifth board of directors will consist of 7 members, including 4 non-independent directors and 3 independent directors, with one non-independent director elected by the employee representative assembly [2]. - The candidates for the fifth board include Cao Yuping, Cao Xicheng, and Feng Mingsheng as non-independent directors, and Lu Tao, Mao Lingxiao, and Wang Yuchun as independent directors [2][3]. Group 2: Candidate Qualifications - All candidates have been vetted and meet the qualifications required by the Company Law and the company's articles of association [2][5]. - Independent director candidates Lu Tao, Mao Lingxiao, and Wang Yuchun have obtained independent director qualification certificates recognized by the Shenzhen Stock Exchange [2][7][9]. Group 3: Election Process - The election of the fifth board of directors will be submitted to the company's first extraordinary general meeting of 2025 for approval, using a cumulative voting system [2][3]. - The term for the new board members will last for three years from the date of approval at the extraordinary general meeting [3]. Group 4: Candidate Profiles - Cao Yuping, born in 1964, holds a master's degree and has extensive experience in the pharmaceutical industry, currently serving as the chairman and general manager of the company [3][4]. - Cao Xicheng, born in 1994, is a master's degree holder and the son of Cao Yuping, currently serving as a director of the company [5]. - Feng Mingsheng, born in 1978, holds a doctoral degree and is currently the deputy manager of the new drug department [6]. - Lu Tao, born in 1963, is a pharmaceutical expert with a doctoral degree and has served in various academic roles [7]. - Mao Lingxiao, born in 1964, is a senior lawyer with extensive legal experience and currently serves as an independent director [8]. - Wang Yuchun, born in 1956, is a professor of accounting with a master's degree and has served as an independent director for other companies [9].

南京海辰药业股份有限公司董事会 附件：职工代表董事简历 证券代码：300584 证券简称：海辰药业 公告编号：2025-033 南京海辰药业股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司（以下简称"公司"）第四届董事会任期即将届 满，根据相关法律法规及《公司章程》关于职工代表董事选举的有关规定，公司 于 2025 年 6 月 23 日在公司会议室召开职工代表大会，经全体与会职工代表审议， 选举褚源红女士为公司第五届董事会职工代表董事（简历详见附件）。 褚源红女士将与公司 2025 年第一次临时股东大会选举产生的三名非职工代 表董事共同组成公司第五届董事会，任期至第五届董事会届满为止。 特此公告。 褚源红女士，1982年出生，中国国籍，无境外永久居留权，本科学历。2018 年毕业于南京大学人力资源管理专业，获管理学学士学位；现任公司人力资源总 监，2003年7月至今，先后任行政人事专员、行政人事主管、人力资源部副经理、 经理等职务；2022年7月至今，担任本公司监事。 截至目前，褚源红女士未持有公司股份，与控股股东、实际控 ...

Core Points - The document outlines the rules for the shareholders' meeting of Nanjing Haichen Pharmaceutical Co., Ltd, ensuring compliance with the Company Law and Securities Law of the People's Republic of China [1][2][3] Group 1: Shareholders' Meeting Procedures - The company must convene shareholders' meetings in accordance with legal and regulatory requirements, ensuring shareholders can exercise their rights [1][2] - Shareholders' meetings can be annual or temporary, with annual meetings held within six months after the end of the previous fiscal year [6][8] - The board of directors is responsible for organizing the meetings and must report to the China Securities Regulatory Commission if unable to convene within the specified timeframe [6][8] Group 2: Voting and Proposals - Proposals for the shareholders' meeting must be within the scope of the meeting's authority and clearly defined [11][12] - Shareholders holding 1% or more of the shares can submit proposals, and the company must notify shareholders of the meeting at least 20 days in advance for annual meetings and 15 days for temporary meetings [11][12] - Voting can occur in person or through authorized representatives, and the company must ensure the voting process is orderly [13][14] Group 3: Decision-Making and Resolutions - Resolutions can be ordinary or special, with ordinary resolutions requiring a simple majority and special resolutions requiring two-thirds approval from attending shareholders [20][22] - Certain significant matters, such as capital changes or major asset transactions, require special resolutions [22][23] - The company must announce the results of the voting and resolutions promptly after the meeting [20][23] Group 4: Related Party Transactions - Related party transactions exceeding 30 million yuan or 5% of the company's net assets must be submitted for shareholders' approval [4][5] - Shareholders with a conflict of interest must abstain from voting on related party transactions [16][17] Group 5: Legal Compliance and Documentation - Legal opinions must be obtained regarding the legality of the meeting procedures and the qualifications of attendees [6] - Meeting records must be maintained for at least 10 years, documenting all proceedings and resolutions [43][44]

南京海辰药业股份有限公司 章 程 目 录 南京海辰药业股份有限公司 章 程 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》 （以下简称《公司法》）、 《中华人民共和国 证券法》（以下简称《证券法》）和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司（以下 简称"公司"），公司系以发起方式设立。公司在南京市市场监督管理局注册登记， 取得营业执照，统一社会信用代码 913201927453675877。 第三条 公司于 2016 年 12 月经中国证券监督管理委员会核准，首次向社会 公众发行人民币普通股 2,000 万股，于 2017 年 1 月在深圳证券交易所（以下简 称"深交所"）上市。 第四条 公司名称： 中文名称：南京海辰药业股份有限公司 英文名称：Nanjing Hicin Pharmaceutical Co., Ltd. 第五条 公司住所：南京市经济技术开发区恒发路 1 号。 第六条 公司注册资本为人民币 12,000 万元。 第七条 公司为永久存续的股份有限公司。 第八条 董事长为代表公司 ...

第二条 薪酬与考核委员会是董事会按照股东会决议设立的专门工作机构， 主要负责制定公司董事及高级管理人员的考核标准并进行考核；负责制定、审查 公司董事及高级管理人员的薪酬政策与方案，对董事会负责。 第三条 本议事规则所称董事是指在本公司支取薪酬的董事长、董事，高级 管理人员是指董事会聘任的总经理、副总经理、董事会秘书、财务负责人以及公 司董事会认定的其他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由三名董事组成，独立董事过半数。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董事或者全体 董事的三分之一提名，并由董事会选举产生。 第六条 薪酬与考核委员会设召集人一名，由独立董事委员担任，负责主持 委员会工作；召集人在委员内选举，并报请董事会批准产生。 南京海辰药业股份有限公司 董事会薪酬与考核委员会议事规则 （2025 年【6】月） 第一章 总则 第一条 为进一步建立健全公司董事（非独立董事）及高级管理人员的考核 和薪酬管理制度，完善公司治理结构，根据《中华人民共和国公司法》《上市公 司治理准则》《公司章程》及其他有关规定，公司董事会特设立董事会薪酬与考 核委员会，并制定本议事规则。 ...

Core Viewpoint - The document outlines the decision-making system for related party transactions of Nanjing Haichen Pharmaceutical Co., Ltd, ensuring fairness, transparency, and protection of investors' rights, particularly for minority shareholders [1][2]. Group 1: Related Party Definition - Related parties include both legal entities and natural persons that have control or significant influence over the company [3][4]. - Legal entities are considered related if they are controlled directly or indirectly by the company or its major shareholders [4][5]. - Natural persons are considered related if they hold more than 5% of the company's shares or are part of the company's management [5][6]. Group 2: Related Party Transactions - Related party transactions involve the transfer of resources or obligations between the company and its related parties, including asset purchases, financial support, and management contracts [6][7]. - Certain transactions, such as cash subscriptions for securities, may be exempt from disclosure and approval processes [7][8]. Group 3: Decision-Making Procedures - The company must ensure that related party transactions do not harm the interests of non-related shareholders and must follow fair pricing principles [8][9]. - Related parties must abstain from voting on matters where they have a conflict of interest during board and shareholder meetings [9][10]. - Transactions exceeding a specified threshold must be evaluated by independent financial advisors and submitted for shareholder approval [10][11]. Group 4: Disclosure and Reporting - The company is required to disclose related party transactions in its annual and semi-annual reports, categorizing them appropriately [11][12]. - Any changes to ongoing related party agreements must be submitted for board or shareholder approval [12][13]. Group 5: Prohibitions and Restrictions - The company is prohibited from providing financial assistance to related parties, with specific exceptions for certain joint ventures [13][14]. - Guarantees provided to related parties must be disclosed and approved by the board and shareholders [14][15].

南京海辰药业股份有限公司 独立董事工作制度 （2025 年【6】月） 第一章 总则 第一条 为完善南京海辰药业股份有限公司(以下称"公司")治理结构，规 范公司运作，更好的维护公司整体利益，保障全体股东特别是中小股东的合法权 益不受损害，根据《中华人民共和国公司法》 （以下称"《公司法》"）、 《上市公司 独立董事管理办法》（以下简称"《管理办法》"）、《上市公司独立董事履职指引》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 （以下简称"《规范运作》"）、 《深圳证券交易所创业板股票上市规则》 （以下简称 "《上市规则》"）《独立董事和审计委员会履职手册》以及《公司章程》（以下称 "《章程》"）的规定，特制定本独立董事工作制度（以下称"本制度"）。 第二条 独立董事系指不在公司担任除董事外的其他职务，并与公司及其 主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行 独立客观判断的关系的董事。 第三条 公司目前设独立董事 3 名。如果《章程》规定的董事会成员人数发 生变更，则公司董事会成员中应当有三分之一以上（包括三分之一）是独立董事， 且至少包括一名会计专业 ...

General Principles - The external guarantee system of Nanjing Haichen Pharmaceutical Co., Ltd. aims to standardize external guarantee behavior, effectively control guarantee risks, and protect shareholders' legal rights [2][3] - The company and its controlling shareholders, directors, and senior management must adhere to the regulations of this system and exercise caution in external guarantees [2][3] Definition and Scope - "External guarantee" refers to the guarantees provided by the company for others, including guarantees for its controlling subsidiaries, excluding guarantees for its own debts [2][3] - A "controlling subsidiary" is defined as a company where the company holds more than 50% of the shares or can control the majority of the board members [3] Principles of External Guarantees - External guarantees must follow principles of equality, voluntariness, fairness, integrity, mutual benefit, strictness, prudence, safety, legality, and standardized operation [3][4] - No individual or entity, including controlling shareholders and related parties, may force the company to provide guarantees [4] Approval Procedures - External guarantees must be uniformly managed by the company, and subordinate departments are prohibited from providing guarantees independently [4][5] - Any external guarantee must be approved by the board of directors and the shareholders' meeting [5][6] Conditions for Providing Guarantees - The company may provide guarantees to entities with independent legal status and strong debt repayment capabilities under specific conditions [9] - Guarantees must require the counterparty to provide counter-guarantees, ensuring the counterparty has the actual capacity to bear the obligation [10] Investigation of the Guaranteed Party - The company must investigate the credit status of the guaranteed party and require them to provide essential documentation, including financial reports and legal compliance statements [11][12] - The company can only provide guarantees if the guaranteed party meets specific credit conditions, such as being a legally established entity with good repayment ability [12][13] Risk Management - After signing a guarantee contract, the finance department is responsible for monitoring and managing subsequent matters related to the guarantee [34] - The company must take necessary remedial measures if the guaranteed party fails to fulfill their debt obligations [35][36] Disclosure Requirements - The company must disclose approved external guarantees on the Shenzhen Stock Exchange website and other media as per regulatory requirements [39] - Timely disclosure is required if the guaranteed party fails to repay debts or faces bankruptcy [40] Responsibilities of Personnel - All directors must carefully manage and control the risks associated with external guarantees and may bear joint liability for losses caused by violations [41][42] - Any unauthorized signing of guarantee contracts by relevant personnel that results in losses to the company will require them to compensate for the losses [42][43]

南京海辰药业股份有限公司 累积投票制实施细则 第一条 为进一步完善公司法人治理结构，规范公司董事的选举行为， 保证股东充分行使权力，根据《公司法》《证券法》及《公司章程》的有关规定， 特制定本实施细则。 第二条 本细则所指累积投票制，是指公司股东会选举两名及两名以上 董事时，出席股东会的股东所拥有的投票权等于其所持有的股份总数乘以应选董 事人数之积，出席会议股东可以将其拥有的投票权全部投向一位董事候选人，也 可以将其拥有的投票权分散投向多位董事候选人，按得票多少依次决定董事人选。 第三条 本实施细则所称"董事"包括独立董事和非独立董事。由职工 代表担任的董事由公司职工民主选举产生或更换，不适用于本实施细则的相关规 定。 第四条 在股东会上，拟选举两名及两名以上的董事时，董事会应当在 召开股东会通知中，表明该次董事选举采用累积投票制。股东会仅选举一名董事 时，不适用累积投票制。 第五条 股东会对董事或候选人进行表决前，大会主持人应明确告知与 会股东对候选董事实行累积投票方式，董事会必须置备适合实行累积投票方式的 选票。董事会秘书应对累积投票方式、选票填写方法做出说明和解释。 第二章 董事的选举及投票 第六条 采 ...

Group 1 - The core viewpoint of the announcement is to establish a standardized external guarantee system to control guarantee risks and protect shareholders' rights [1][2] - The external guarantee is defined as the company providing guarantees for others, excluding guarantees for its own debts [1] - The total amount of external guarantees includes guarantees provided by the company to its subsidiaries and those provided by subsidiaries to third parties [1] Group 2 - The guarantee system emphasizes principles such as equality, voluntariness, fairness, integrity, mutual benefit, strictness, prudence, safety, legal compliance, and standardized operations [1] - Guarantees can only be provided to entities with independent legal status and strong debt repayment capabilities, and must include counter-guarantees from the other party [1][2] - The approval process for guarantees requires board review and timely disclosure, with certain guarantees needing shareholder approval based on specific conditions [2] Group 3 - Guarantee contracts must be in writing and include multiple specified clauses, with a review of relevant content during contract formation [2] - The company has implemented various measures for guarantee risk management, including oversight by the finance department and pursuing recovery after fulfilling guarantee obligations [2] - The system clarifies the responsibilities of directors and senior executives in external guarantees, emphasizing the independence of guarantee decision-making by controlling shareholders [2]